• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
 
DeviceCARDIAC RESYNCHRONIZATION THERAPY PACEMAKER (CRT-P) DEVICES
Classification Namepulse generator, pacemaker, implantable, with cardiac resynchronization (crt-p)
Generic Namepulse generator, pacemaker, implantable, with cardiac resynchronization (crt-p)
Applicant
MEDTRONIC Inc.
8200 coral sea street ne
ms mv s11
mounds view, MN 55112
PMA NumberP010015
Supplement NumberS205
Date Received05/29/2013
Decision Date04/10/2014
Product Code
NKE[ Registered Establishments with NKE ]
Docket Number 14M-0553
Notice Date 05/08/2014
Advisory Committee Cardiovascular
Clinical Trials NCT00267098
Supplement Typepanel track
Supplement Reason labeling change - indications/instructions/shelf life/tradename
Expedited Review Granted? Yes
Combination Product No
Approval Order Statement 
Approval for the expansion of the indications for use of the crt-p and crt-d devices to include nyha functional class i, ii, or iii patients who have a left ventricular ejection fraction (lvef) => 50% are on stable, optimal heart failure medical therapy if indicated, and have atrioventricular block (av block) that is expected to require a high percentage of ventricular pacing that cannot be managed with algorithms to minimize right ventricular pacing. These devices are indicated for the following: the consulta crt-p system is indicated for: 1) nyha functional class iii and iv patients who remain symptomatic despite stable, optimal heart failure medical therapy and have a lvef =< 35% and a prolonged qrs duration; and 2) nyha functional class i, ii, or iii patients who have a lvef =<50% are on stable optimal heart failure medical therapy if indicated and have atrioventricular block (av block) that are expected to require a high percentage of ventricular pacing that cannot be managed with algorithms to minimize right ventricular pacing. For additional information please refer to approval order.
Approval Order Approval Order
Summary Summary of Safety and Effectiveness
Labeling Labeling
Labeling Part 2
-
-